2/ Why now? The convergence of breakthrough science in aging + accelerant technology (including AI) has sparked a new wave of startups. Visionaries are betting on longevity to be the next big thing: Bezos ($3B Altos) Sam Altman ($180M Retro Bio) Brian Armstrong ($105M NewLimit)

3/ Problem: The longevity field is noisy. It’s hard to separate the science from the snake oil. Our report dives deep into companies working on real therapeutic innovations – from mitochondrial transfer, cell reprogramming, replacement +more.

4/ We’ve broken down the landscape of longevity biotech across five core technological approaches: •Removal •Replacement •Reprogramming •Metabolic modulation •Non-specific Discovery Platforms

5/ …and analyze key differentiators, funding, pipelines, foundational innovation of 46 leading companies in our report.

6/ The longevity biotech sector represents one of the largest market opportunities of our time. With age-related diseases causing ~100,000 daily deaths worldwide + rapidly aging populations, the need for innovative therapeutic approaches has never been more urgent.

7/ Whether you're from longevity, biotech, tech, or just curious about the future of aging - this is your roadmap to the field. 👇Read the LongBio Report 2025 here:

PS: We want to highlight Healthspan Capital venture fellow @AVTchernev for his incredible work in spearheading this report. Also want to thank all our friends, portfolio companies, and colleagues in the industry who provided valuable input and feedback.  🧬♾️